Finance

Beta
Lists
Equity sectors
Symbols
Symbols
Price
Change
% Change
Trend
Prev Close
Open
High
Low
Volume
Mkt Cap
SIXB
Materials
SIXB
Materials
SIXB
-0.32%
1,100.57
-3.53
-0.32%
—1,104.101,103.921,108.751,097.16——
SIXC
Communications
SIXC
Communications
SIXC
+0.16%
605.15
+0.99
+0.16%
—604.16604.16610.19604.12——
SIXE
Energy
SIXE
Energy
SIXE
-0.22%
1,195.19
-2.62
-0.22%
—1,197.811,200.581,213.071,192.02——
SIXI
Industrials
SIXI
Industrials
SIXI
-0.03%
1,739.91
-0.50
-0.03%
—1,740.411,739.551,750.271,730.60——
SIXM
Financials
SIXM
Financials
SIXM
+0.65%
638.56
+4.12
+0.65%
—634.44633.13639.87633.01——
SIXR
Staples
SIXR
Staples
SIXR
-1.11%
831.57
-9.33
-1.11%
—840.90839.53841.73831.10——
SIXRE
Real estate
SIXRE
Real estate
SIXRE
-0.82%
213.36
-1.77
-0.82%
—215.13215.13215.85213.24——
SIXT
Technology
SIXT
Technology
SIXT
+0.17%
3,234.18
+5.47
+0.17%
—3,228.713,225.623,235.433,198.95——
SIXU
Utilities
SIXU
Utilities
SIXU
-0.02%
935.65
-0.22
-0.02%
—935.87938.37942.00935.65——
SIXV
Health care
SIXV
Health care
SIXV
-0.54%
1,449.26
-7.86
-0.54%
—1,457.121,452.741,466.881,449.18——
SIXY
Discretionary
SIXY
Discretionary
SIXY
-0.72%
2,382.45
-17.39
-0.72%
—2,399.842,389.712,394.612,371.22——
ARCT:NASDAQ
Arcturus Therapeutics Holdings Inc
$8.30
-3.38%
(-0.29) 1D
$8.30
0.00% (0.00)
After hours
Closed: Apr 27, 4:00:01 PM GMT-4  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for ARCT...
Open
$8.58
High
$8.80
Low
$8.28
Mkt. cap
235.91M
Avg. vol.
500.42K
Volume
254.35K
52-wk high
$24.14
52-wk low
$5.86
EPS
-$2.40
Beta
2.44
Shares outstanding
28.42M
No. of employees
109
News stories
From sources across the web
Profile
Arcturus Therapeutics Holdings Inc. is an American RNA medicines biotechnology company focused on the discovery, development and commercialization of therapeutics for rare diseases and infectious diseases. Arcturus has developed proprietary lipid nanoparticle RNA therapeutics for nucleic acid medicines including small interfering RNA, messenger RNA, gene editing RNA, DNA, antisense oligonucleotides, and microRNA. The company develops RNA therapeutics for the treatment of rare diseases such as ornithine transcarbamylase deficiency, and respiratory diseases such as cystic fibrosis. Vaccine medicines include a vaccine candidate for COVID-19 and an influenza vaccine in the preclinical development phase. The vaccine for COVID-19 was authorised in Japan in 2023 and the European Union in 2025. Wikipedia
About Arcturus Therapeutics Holdings Inc
CEOJoseph E. Payne
Employees109
Founded2013
Headquarters-
SectorBiotechnology
Websitearcturusrx.com
Previous reportsAll values in USD
Loading Previous Earnings...
Income statement
Revenue
Net income
All values in USD
Mar 2025
Jun 2025
Sep 2025
Dec 2025
Revenue
29.38M
28.30M
17.15M
7.20M
Cost of goods sold
34.89M
29.58M
23.26M
24.48M
Cost of revenue
34.89M
29.58M
23.26M
24.48M
Research and development expenses
-
-
-
-
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
11.32M
10.34M
10.40M
14.03M
Operating expense
11.32M
10.34M
10.40M
14.03M
Total operating expenses
46.21M
39.92M
33.66M
38.50M
Operating income
-16.83M
-11.62M
-16.51M
-31.31M
Other non operating income
-
-
-
-
EBT including unusual items
-14.08M
-9.18M
-13.45M
-29.08M
EBT excluding unusual items
-14.08M
-9.18M
-13.45M
-29.08M
Income tax expense
-
4.00K
-
-4.00K
Effective tax rate
-
-0.04%
-
0.01%
Other operating expenses
-
-
-
-
Net income
-14.08M
-9.18M
-13.45M
-29.08M
Net profit margin
-47.91%
-32.44%
-78.41%
-404.10%
Earnings per share
-0.52
-0.34
-0.49
-1.03
Interest and investment income
2.77M
2.57M
3.23M
1.53M
Interest expense
-
-
-
-9.00K
Net interest expenses
2.77M
2.57M
3.23M
1.52M
Depreciation and amortization charges
-
-
-
-
EBITDA
-16.02M
-10.84M
-15.75M
-30.62M
Gain or loss from assets sale
-
-
-
-
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer

Research

My tasks
You haven't created a task yet
Your tasks will appear here. Schedule tasks and put Google Finance to work while you're away.
Templates
Watchlist briefing
A daily pre-market analysis of your watchlist
Upcoming Earnings
Upcoming earnings reports in the week
Abnormal Volatility & Volume
Volatility and volume early warning today
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer